Prevention of behavioral deficits in rats exposed to folate receptor antibodies: implication in autism

Mol Psychiatry. 2017 Sep;22(9):1291-1297. doi: 10.1038/mp.2016.153. Epub 2016 Sep 20.

Abstract

Folate receptor alpha (FRα) autoantibodies have been associated with fetal abnormalities and cerebral folate deficiency-related developmental disorders. Over 70% of the children with autism spectrum disorders (ASD) are positive for these autoantibodies and high-dose folinic acid is beneficial in treating these children. Here we show that antibodies (Abs) to the rat FRα administered during gestation produce communication, learning and cognitive deficits in a rat model that can be prevented by folinic acid and dexamethasone. FRα Ab can trigger inflammation as well as block folate transport to the fetus and to the developing brain to produce the functional deficits. In humans, exposure to FRα autoantibodies during fetal development and infancy could contribute to brain dysfunction such as that seen in ASD and other developmental disorders. Identifying women positive for the autoantibody and treating them with high-dose folinic acid along with other interventions to lower the autoantibody titer are effective strategies that may be considered to reduce the risk of having a child with developmental deficits.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies
  • Autistic Disorder / drug therapy*
  • Autistic Disorder / immunology*
  • Autistic Disorder / metabolism
  • Autoantibodies / immunology
  • Child
  • Cognition Disorders / drug therapy
  • Dexamethasone / therapeutic use
  • Female
  • Folate Receptor 1 / antagonists & inhibitors
  • Folate Receptor 1 / deficiency*
  • Folate Receptor 1 / immunology
  • Folate Receptor 1 / metabolism
  • Folic Acid
  • Humans
  • Leucovorin / therapeutic use
  • Male
  • Pregnancy
  • Rats
  • Rats, Long-Evans

Substances

  • Antibodies
  • Autoantibodies
  • Folate Receptor 1
  • Dexamethasone
  • Folic Acid
  • Leucovorin